About: acn

ISTANBUL, October 18, 2024 - (ACN Newswire via SeaPRwire.com) - The 15th Turkish-Arab Economic Forum (TAFF 2024), aimed at deepening relations between Turkiye and the Gulf countries and defining joint strategies for the region, took place yesterday in Istanbul.The Forum saw the attendance of many key figures from the Gulf countries, including Kuwait's Minister of Finance Noora Suleiman Salem Al-Fassam, Iraq's Minister of Finance Taif Sami Mohammed, Egypt's Deputy Minister of Finance Ahmed Kouchouk, Tunisia's Minister of Economy and Planning Samir Abdelhafidh, Libya's Minister of Finance Dr Kalid Al-Mabrouk, President of the Turkish Investment Fund Baghdad Amreyev, Secretary General of the Egyptian Federation of Arab Chambers Dr Khaled Hanafy, Regional Director of the Saudi International Finance Corporation Fawaz Bilbeisi, Director of the World Bank GCC Cooperation Safaa El Tayeb El-Kogali, Partner at the UK's DWF Solomon Ebere, Board Member of the Qatar Chamber Mohamed Bin Ahmed Al Obaidly, and Vice President of International Business Development of the United Arab Emirates Khalid Al Marzooqi.Turkiye's Minister of Treasury and Finance Mehmet Simsek evaluated global and regional strategies.In his speech at the 15th Turkish-Arab Economic Forum, Minister of Treasury and Finance Mehmet Simsek highlighted the decline in inflation and the slowdown in monetary policies. He emphasized that global trade will continue in November, pointing out that while there are challenges, there are also opportunities in this process. Mehmet Simsek further noted that he expects an increase in cooperation across various sectors, emphasizing that partnerships in energy, manufacturing, technology, and machinery are crucial for realizing the region's potential and he expressed his support for diversification strategies.Dr. Erkan Kork stated that Turkiye and the Gulf countries could build a shared future.Speaking at the 15th Turkish-Arab Economic Forum, Dr. Erkan Kork, Chairman of the Board of BankPozitif, highlighted that the participating countries share the same geography, history, and values, and emphasized that joint steps would be stronger and more effective. He noted that building a shared future with the available know-how, technology, and investments is vital for unlocking the region's potential.BankPozitif Chairman Dr Erkan Kork at the 15th Turkish Arab Economic ForumExpressing pride in Turkiye's positioning as a fintech hub, Dr Erkan Kork predicted that Turkiye would play a leading role on the global stage in various fields in the near future. He also stressed the importance of forums, fairs and events like this for fostering relationships between the business world and governments of different countries.In his speech, Dr Erkan Kork pointed out that Turkiye is in a very strong position in terms of innovation and information technology, noting that while processing times in many sectors in Europe are long, they are much shorter in Turkiye. Dr. Erkan Kork also highlighted Turkiye's high level of competitiveness in recent years.At the forum, which had a high participation rate, Fatih Karahan, Governor of the Central Bank of the Republic of Turkiye, Burak Dagloglu, Member of the Board of Directors of the Turkiye Wealth Fund, and Rfat Hisarckloglu, President of the Union of Chambers and Commodity Exchanges of Turkiye, were also among the speakers.Source: BankPozitif, https://www.bankpozitif.com.trSait Inanc, +90533 722 49 69, info@bankpozitif.com.tr* This press release is issued through EuropeNewswire.Net (www.europenewswire.net) and distributed by EmailWire  (www.emailwire.com) – the gloabal newswire that provide Press Release Distribution with Guaranteed Results™. Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the "Hong Kong and Macau Medicine and Equipment Connect" policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.In addition, on 24 September, the NDA for vitiligo indication of ruxolitinib cream has been accepted by the National Medical Products Administration of China (NMPA). In accordance with the relevant regulations of the drug real-world data application pilot program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), CMS has conducted a real-world study on ruxolitinib cream in China. The results have shown positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Meanwhile, through the safety monitoring data of the Pilot Zone, no new safety events have been identified. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.If the Product is successfully approved for marketing in Mainland China, it will be the first prescription drug approved by NMPA for repigmentation in vitiligo, bringing this novel treatment hopes for Chinese vitiligo patients.Furthermore, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Pilot Zone on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. As of 30 June 2024, more than 3,200 patients have been treated with ruxolitinib cream in Boao Super Hospital.CMS has always been patient-oriented and innovation-driven based on clinical needs, continuously striving to improve drug accessibility. Benefited from the "Hong Kong and Macau Medicine and Equipment Connect" policy, ruxolitinib cream was approved for use in the Greater Bay Area and completed its first batch of prescriptions, shortening the time difference for Chinese vitiligo patients to use innovative drug and benefiting more domestic patients. Looking forward to the future, the Group will continuously strive to meet the unmet needs of Chinese patients, continuously explore novel drugs with international quality, and efficiently promote products’ clinical development and commercialization, so as to bring more quality pharmaceutical products through differentiated innovation-breakthrough, to safeguard the health and life-quality of patients.About ruxolitinib creamRuxolitinib cream (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. As of now, it is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[2]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.About vitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[4]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[5,6].About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2. Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3. Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75. Consensus on the diagnosis and treatment of vitiligo (2021 version)6. Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

深圳, 2024年10月18日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，磷酸蘆可替尼乳膏（「蘆可替尼乳膏」或「產品」）在中山陳星海中西醫結合醫院、佛山複星禪誠醫院、以及東莞松山湖東華醫院為符合條件的白癜風患者開出大灣區首批處方。產品於2024年4月11日獲得澳門政府藥物監督管理局（ISAF）批准新藥上市申請，隨後通過「港澳藥械通」政策，並於8月19日獲得廣東省藥品監督管理局批准，正式落地粵港澳大灣區內地指定醫療機構，用於12歲及以上青少年和成人患者伴面部受累的非節段型白癜風的治療，為相關適應症患者提供了全新治療選擇。此外，蘆可替尼乳膏白癜風適應症新藥上市許可申請已於9月24日獲得中國國家藥品監督管理局（NMPA）受理。根據海南博鰲樂城國際醫療旅遊先行區藥品真實世界數據應用試點程式有關規定，蘆可替尼乳膏在中國開展真實世界研究，療效積極，與境外關鍵臨床研究結果一致。所有的次要療效指標均顯示出與主要療效指標一致的獲益趨勢，且治療時間越長，患者的白癜風治療效果持續改善。同時利用了樂城先行區安全監測數據，未發現新的安全性事件。不良反應的嚴重程度大部分均為1級或2級，未發生導致停藥或退出的不良事件（AE），未發生研究藥物相關的嚴重不良事件（SAE）。若產品於中國大陸獲批上市，其有望成為首個經NMPA批准用於白癜風複色的處方藥，將為中國廣大白癜風患者帶來治療新曙光。除上述進展外，產品此前於2023年8月12日獲得海南省藥監局批準臨床急需進口，並於8月18日正式落地海南博鰲樂城國際醫療旅遊先行區，用於12歲及以上青少年和成人患者伴面部受累的非節段型白癜風的局部治療。受益于國家賦予海南自由貿易港、博鰲樂城國際醫療旅遊先行區「先行先試」特許政策，中國白癜風患者可在博鰲超級醫院先行申請使用產品並接受專家團隊的治療。截至2024年6月30日，已有超3,200例患者在博鰲超級醫院使用蘆可替尼乳膏進行治療。康哲藥業始終以患者為中心，以臨床需求驅動創新，為提升藥物可及性而持續努力。本次蘆可替尼乳膏得益於「港澳藥械通」政策支持，先行獲批引入大灣區，並完成首批處方落地，縮短了中國白癜風患者使用創新藥的用藥時差，讓更多國內白癜風患者獲益。展望未來，康哲藥業將繼續為滿足中國患者未盡之需而奮進，持續挖掘國際品質的新藥、好藥，高效推動產品臨床開發和商業化發展，以差異化的創新突破為病患帶來更多優質的醫藥產品，為守護患者健康生活和生命質量貢獻力量。關於蘆可替尼乳膏蘆可替尼乳膏（Opzelura），為Incyte的JAK1/JAK2選擇性抑制劑蘆可替尼的創新乳膏製劑，已獲得美國食品和藥物管理局（FDA）批準用於12歲及以上非節段型白癜風患者的局部治療。截至目前，蘆可替尼乳膏是首個也是唯一一種在美國獲批使用的白癜風複色產品[1]。此外，產品在美國獲批用於傳統外用處方療法不可取或不能充分控制病情之12歲及以上非免疫功能低下的輕中度AD患者的局部短期和非持續性慢性治療[2]。產品也於歐洲獲批用於12歲及以上青少年及成人患者伴面部受累的非節段型白癜風的治療[3]。康哲藥業於2022年12月2日，通過其附屬公司-康哲美麗與Incyte就用於治療自身免疫性炎症皮膚病的蘆可替尼乳膏製劑訂立合作和許可協議（「許可協議」）。根據該等許可協議，康哲藥業通過康哲美麗獲得在中國大陸、香港特別行政區、澳門特別行政區、台灣地區及東南亞十一國（印尼、菲律賓、越南、泰國、緬甸、馬來西亞、柬埔寨、老撾、新加坡、東帝汶以及文萊）（「區域」）開發、註冊及商業化產品的獨家許可權利，以及在區域內生產產品的非獨家許可權利。許可協議期限開始於許可協議生效日，自產品在區域內首次商業化銷售之日起擁有十年的授權期限（「授權期限」）。授權期限屆滿後，根據許可協議約定的特定條件，許可協議期限可延長十年（「初始延展授權期限」）。初始延展授權期限屆滿後，根據許可協議約定的特定條件，雙方可另行協商許可協議的延長期限。Incyte擁有產品的全球開發和商業化權利，產品在美國及歐洲以Opzelura®的名稱銷售。Opzelura及其logo為Incyte的注冊商標。關於白癜風白癜風是一種慢性自身免疫性疾病，其特徵是皮膚色素脫失，其發病原因為產生色素的細胞即黑素細胞的缺失。據估算，中國白癜風患者約1,400萬[4]。白癜風患者中約85%為非節段型白癜風。外用皮質類固醇（TCS）及鈣調神經磷酸酶抑制劑（CI）均為非節段型白癜風的標籤外用藥，然而，這些現有外用藥物療法有長期用藥的不良反應或療效有限的臨床痛點[5、6]。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平台型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化業務競爭力，並將皮膚醫美、眼科業務獨立運營，培育專科小領域的大龍頭，提升專科規模效率。同時業務版圖拓展至東南亞市場，著力成為全球藥企進軍東南亞市場的「橋頭堡」，助力康哲藥業高品質持續健康發展。參考文獻/資料：1、FDA批準信息可在FDA官網查詢，網址：https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2、FDA批準信息可在incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3、EMA批準信息可在EMA官網查詢，網址：https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4、Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75、《白癜風診療共識（2021版）》6、Kubelis-Lopez DE, Zapata-Salazar NA, Said-Fernandez SL, Sanchez-Dominguez CN, Salinas-Santander MA, Martinez-Rodriguez HG, Vazquez-Martinez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2024 亞太商訊 via SeaPRwire.com.

Washington, D.C., Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - Today marks the launch of the second edition of the Multilateralism Index from the International Peace Institute (IPI) and the Institute for Economics & Peace (IEP). The Index reveals that states remain engaged in the global multilateral system even as it increasingly struggles to address the crises it faces.Multilateralism Index 2024 ReportAn image of the front cover of the Multilateralism Index 2024 ReportKey resultsThe performance of the multilateral system declined across all five domains examined.Peace and security showed the steepest deterioration in performance, with the number of armed conflicts rising from 39 in 2013 to 55 in 2022.Climate action and human rights also saw significant declines in performance, despite increased engagement from member states.Participation in multilateral institutions has increased in most domains, even as performance has declined, indicating a shift from cooperation to contestation.Inclusivity improved across all domains, with steady growth in NGO engagement and women's representation in UN bodies.The Multilateralism Index 2024 presents a complex picture of global cooperation over the past decade, examining five crucial domains: Peace and Security, Human Rights, Climate Action, Public Health, and Trade. It reveals a contradiction: while participation in the multilateral system has largely held steady or even increased, its effectiveness in addressing global challenges has declined.Dr. Adam Lupel, IPI Vice President & COO said: "Over the past decade, we've witnessed a paradox in multilateralism. While participation in international institutions has largely held steady or even increased, the performance of the multilateral system in addressing global challenges has declined. This suggests a shift from cooperation to contestation at a time of transformation and rising global crises."The peace and security domain experienced the most significant deterioration in performance. Active armed conflicts increased from 39 in 2013 to 55 in 2022, with a notable rise in internationalized conflicts. The UN Security Council has seen more frequent use of the veto power, constraining its ability to respond to crises. However, states have not broadly pulled back from the UN peace and security architecture, and commitments in some areas, such as multilateral peacebuilding, have increased.Climate action presents another contradiction. Despite near-universal participation in the Paris Agreement and growing climate commitments, these commitments continue to fall short of necessary targets. Projections show an 8.8% increase in emissions by 2030, in stark contrast to the 43% decrease required to meet the critical 1.5°C target.The human rights domain exhibits a counterintuitive pattern. While engagement with UN human rights mechanisms has increased, global human rights protections have steadily declined. Most strikingly, members of the UN Human Rights Council consistently scored lower on human rights measures than the global average, indicating that many states are engaging less to advance human rights than to shape the direction of the system.Multilateral action on public health was significantly shaped by the COVID-19 pandemic, which reversed years of progress, particularly in areas such as childhood immunization. It also put the shortcomings of the global public health system in stark relief, spurring negotiations on an international pandemic agreement aimed at strengthening preparedness and response capabilities for future health crises.Trade is the one area where both performance and participation decreased. The paralysis of global trade negotiations and breakdown in adherence to global trade rules signal a shift away from multilateral approaches. This trend, combined with growing geopolitical tensions, creates challenges for global economic cooperation.Steve Killelea, Founder & Executive Chairman of IEP, commented: "The Multilateralism Index 2024 reveals a challenging trend: while engagement in global institutions has increased, their effectiveness has declined across key areas. There is a need to revitalize our multilateral system to address today's complex challenges."Despite these challenges, the Index highlights positive developments, particularly in the area of inclusivity. NGO engagement with the UN system has grown, and women's representation has increased across many UN bodies. However, the Global South remains underrepresented in many areas, suggesting that geographic inclusivity remains a work in progress.As the world contends with interconnected crises, from conflict to climate change, the Multilateralism Index 2024 provides valuable insights into the current state of global cooperation. It underscores the need for thoughtful reform to ensure that multilateral institutions can effectively address the complex challenges of the 21st century.Contact InformationMike KoslowskiIEP Senior Communications Advisormkoslowski@economicsandpeace.org+61418410531Related FilesMultilateralism Index 2024 - Full Press Release (1)Multilateralism Index 2024 - Full Press Release (1)SOURCE: International Peace Institute Copyright 2024 ACN Newswire via SeaPRwire.com.

San Francisco, CA & Hanoi, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - VPBank, one of Vietnam’s largest private banks, partners with CleverTap, the all-in-one customer engagement platform, to deepen understanding of customers and their aspirations and use the insights to deliver hyper-personalized experiences to users, at scale. VPBank aims to elevate customer experience and drive higher conversions on products and offers through highly targeted campaigns built on complex, real-time segmentation that quickly connects with customers. Through this association with CleverTap, VPBank’s objective is to improve engagement, deepen relationships and drive higher retention, while keeping costs low.Established in 1993, VPBank operates in a wide variety of businesses including retail banking, corporate banking, wealth management, and consumer finance. VPBank aims to become a top-ranking financial institution among joint stock commercial banks in Vietnam, in terms of business scale, market share, and service quality. Leveraging CleverTap’s AI/ML-powered capability suite, Clever.AI, VPBank will be able to hyper-personalize its engagement via multiple automation and journeys. It will enable a seamless and omnichannel onboarding experience for new users, driving higher success rates for key milestones such as registration and the first transaction. With the unified customer view on CleverTap, VPBank can identify high-intent users and target them with contextual and relevant offerings, achieving an increase in customer lifetime value.Varun Krishna, Head of Digital Marketing, VPBank said, “We’ve always strived to maintain our position as one of Vietnam’s leading financial institutions. In an increasingly competitive banking landscape, delivering personalized and meaningful customer experiences is paramount. Partnering with CleverTap empowers us to harness advanced AI-driven insights, enabling us to engage our customers more effectively and tailor our offerings to their unique needs across digital channels. This collaboration not only enhances our ability to connect with customers on a deeper level but also drives sustained growth and loyalty. Together, we are committed to setting new standards in customer engagement and positioning VPBank as the most trusted and preferred bank in Vietnam.”Mai Vo, Country Manager, CleverTap said, “Vietnam’s banking sector is at the precipice of a new era of growth. Our partnership with VPBank couldn’t be timed better. With a legacy of innovation and customer-centricity, VPBank has consistently set benchmarks in the Vietnamese banking industry. Their commitment to using technology for crafting exceptional customer experiences aligns perfectly with our vision. Together, with CleverTap’s state-of-the-art omnichannel platform, personalizing and enhancing customer engagement has never been more seamless. This partnership is not only a testament to CleverTap’s expertise in driving conversion and retention but also underscores VPBank’s leadership in propelling Vietnam's banking sector into a new era of excellence”About CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Domino’s, Levis, Jio, Papa John’s, Zomato, Kotak Bank, Air Asia, Carousell, TD Bank, and Tesco to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit clevertap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/  X: https://twitter.com/CleverTap  Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications, CleverTap+91 9820900036sony@clevertap.com  ASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co  Copyright 2024 ACN Newswire via SeaPRwire.com.

ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activitiesNo serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK) The data provides clinical verification for Athos’ Proprietary AI2 (Artificial Intelligence for Autoimmune drug development) computational software platform which generated ATH-063LOS ANGELES, CA, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, today announced topline results for the company's Phase 1 clinical trial of ATH-063, an investigational oral small molecule G9A inhibitor and the company's lead asset in development for the treatment of inflammatory bowel disease (IBD).The clinical trial was a randomized, double-blind, placebo-controlled study in healthy volunteers designed to evaluate safety and PK as well as provide pharmacodynamic (PD) data to provide confirmation of ATH-063's proposed mechanism of action. The trial was conducted as sequential single ascending dose (SAD) (n=32) and multiple ascending dose (MAD) (n=32) arms, and a separate food-effect (FE) (n=12) arm. Four doses (25, 75, 150, and 250 mg) of ATH-063 were administered orally.PD data showed ATH-063 selective expansion and activation of Tregs, consistent with predictions made by Athos' AI2 platform:Statistically significant increases (p<0.001) in the number of blood Tregs were observed at all ATH-063 dose levels compared to placebo subjects, and demonstrated correlation between ATH-063 blood levels and number of TregsBlood ATH-063 concentration positively correlated with increase in multiple key biomarkers of Treg activity, including strong correlation with FOXP3 (p=0.003)Induced Tregs demonstrated enrichment of six well-described genes related to Treg anti-inflammatory activitiesSTAT5A, a key signaling molecule related to induced Tregs, was activated in all cohorts and doses (p=0.0003)PD data demonstrated correlation with key biomarkers of IBD disease activity, supporting further development of ATH-063 as a treatment for IBD:Blood ATH-063 concentration correlated (p=0.012)with reduction of OSM, a well-established biomarker related to TNFA resistanceBlood ATH-063 concentration correlated with reduction of calprotectin monomers, which is an established biomarker for IBDATH-063 was well tolerated across all dose groups: No serious adverse effect or dose limiting toxicities were observed at any dose levelRobust PK results and dose proportional increases in blood levels: ATH-063 showed favorable PK results with dose-proportional increases in blood ATH-063 concentrations throughout the study"The results of our first-in-human clinical trial of ATH-063 exceeded our high expectations," said Dimitrios Iliopoulos, PhD, MBA, Founder, President & CEO, Athos. "We used the Athos AI2 drug development platform to identify a previously unrecognized and novel therapeutic target, to create ATH-063, and to preclinically predict the compound's proposed mechanisms of action. We are delighted that these Phase 1 results serve as clinical verification for the predictions made by the Athos AI2 computational engine" added Dr. Iliopoulos."Our Phase 1 data showed that once daily, oral dosing of ATH-063 was well tolerated and showed expansion of Tregs," commented Allan Pantuck, MD, MS, FACS, Chairman, Founder & CMO. "We are excited to move to our next stage of clinical development in subjects with moderately to severely active ulcerative colitis. The rapid pace of the ATH-063 program, from initial target identification to a completed Phase 1 trial, was enabled by the use of our innovative approach to leveraging Artificial Intelligence for drug development."About ATH-063ATH-063 is a novel, investigational, AI-generated, oral, small molecule, G9A inhibitor in development for the treatment of inflammatory bowel disease and other autoimmune diseases. G9A is a central hub on a gene network that was identified by the Athos AI2 platform through the integration of multi-omic and longitudinal clinical data from Athos' IBD biorepository. ATH-063 is designed to directly target G9A enzymatic activity in human CD4 T cells and GI epithelial cells, acting both by suppressing pro-inflammatory responses through expansion and activation of regulatory T cells and inducing direct mucosal healing through regulation of tight junction proteins.About Athos TherapeuticsAthos Therapeutics is a clinical stage biotechnology company seeking to develop potential first-in-class therapeutics that significantly impact the lives of patients with autoimmune disorders and chronic inflammatory diseases. The Athos drug development platform begins with over 25,000 high-quality patient samples sourced from premier global hospital systems. Athos' AI2 platform identifies novel drug targets by integrating multi-omic and longitudinal clinical datasets and matches them to its small molecule computational chemistry platform. The AI2 platform includes the Athos data lake, singular well-established omics workflows, and an integrative deep machine learning engine. The company's lead drug compound is ATH-063, an investigational, oral small molecule G9A inhibitor for inflammatory bowel disease.Athos is also developing a pipeline of additional small molecule approaches for various autoimmune diseases.Additional information about Athos Therapeutics can be found at https://athostx.com/Contact:Athos Therapeutics, Inc.Keith Hoffman, PhD, Chief Business Officerkhoffman@athostx.comSOURCE: Athos Therapeutics, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.

- The two major electronics fairs concluded today, attracting over 60,000 industry buyers from 136 countries and regions- 53% of respondents in an on-site survey expect overall sales to increase over the next 12-24 months, while 43% expect sales to remain stable- Most respondents believe there is a “very promising” or “promising” market potential for wearable electronic products (65%) and robotics technology (59%)HONG KONG, Oct 16, 2024 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Electronics Fair (Autumn Edition), organised by the Hong Kong Trade Development Council (HKTDC), and electronicAsia, jointly organised by the HKTDC and MMI Asia Pte Ltd, concluded their physical exhibitions today.The four-day events attracted more than 60,000 industry buyers from 136 countries and regions. The number of buyers from Malaysia, Türkiye, Argentina and the UAE increased from last year. This reflects the exhibitions' status as important sourcing platforms for the industry.Sophia Chong, Deputy Executive Director of the HKTDC, said: "The global trend towards smart living is driving demand for innovative products and solutions. The Electronics Fair and electronicAsia serve as efficient platforms for the industry, enabling exhibitors to showcase their electronic products and technology solutions to buyers. We are pleased to see exhibitors and buyers successfully exploring business opportunities at the exhibitions, which are expediting Hong Kong's development into an international innovation and technology (I&T) centre.”In late October, the HKTDC will host the Hong Kong International Lighting Fair (Autumn Edition), Hong Kong International Outdoor and Tech Light Expo and ECO Expo Asia to create more cross-industry business opportunities.Industry optimistic about India, the Middle East, Latin AmericaAn independent survey agency commissioned by the HKTDC interviewed 1,091 Electronics Fair buyers and exhibitors about growth prospects for the industry. 53% of respondents expect overall sales to increase in the next 12-24 months, while 43% anticipate that they will remain stable. Most respondents believe that the electronics industry has the most growth potential in emerging markets, such as India, the Middle East and Latin America over the next two years, followed by Korea, Mainland China, Australia and the Pacific Islands.In terms of trends in electronic products, most respondents believe there is a “very promising” or “promising” market potential for wearable electronic products (65%) and robotics technology (59%).Meanwhile, 56% of respondents believe that the market potential for e-sports products and equipment is high. Most respondents consider these products to have the greatest growth potential in North America and Northern and Western Europe.Exhibitors attract quality buyers at fairsThis year's Electronics Fair featured more than 20 zones, gathering the latest electronic products and innovative solutions from global exhibitors in areas such as smart cities, smart mobility, gerontechnology and digital entertainment.First-time exhibitor and Founder of Zunosaki Limited, Newmen Ho, promoted the company's hand rehabilitation robot in the Startup Zone, seeking Mainland China and overseas distributors, partners and investors. In the first half of the exhibition, he met potential buyers from Taiwan’s nursing homes and from Korea. Additionally, a buyer from India expressed interest in applying the company's robotic hand technology across different industries.Hong Kong's renowned consumer electronics brand Momax achieved impressive results at the fair. The company's Founder and CEO John Cheng stated that in the first two days of the Fair, the team met some 60 buyers from the Asia-Pacific region and Europe. Momax also formed a long-term partnership with a publicly listed company in Papua New Guinea and is currently discussing an initial order valued at US$50,000.Additionally, through HKTDC’s Click2Match smart business matching platform, the company connected with another quality buyer from Australia, with the intent to collaborate long-term. Mr Cheng said: "Hong Kong's exhibitions are world-class, featuring high-quality buyers from a diverse range of countries. This year's Autumn Electronics Fair saw a significant turnout, and the buyers were very engaged. We will definitely participate again next year."Dongguan Maochang Printed Circuit Board Ltd, which develops technological solutions, participated in electronicAsia to stay updated on industry trends and identify potential buyers. The company's Sales Director, Michael Tsang, said: "Expanding onto the international stage is our primary goal for participating in the exhibition. I am glad that we met with over 200 potential buyers in the first three days to gain a deeper understanding of customer needs."Buyer seeks new products to expand marketVinal Patel, Chief Commercial Officer of UK buyer Brand Collective, has been attending the Electronics Fair for over 20 years. During the first two days of this year's fair, he secured over US$2 million worth of purchases, including charging cables, power banks and wireless speakers from two exhibitors. He is also considering expanding the range of products he distributes after discovering new offerings at the Fair. Mr Patel said: "The line-up at the exhibition gets better every year, even more impressive than before the pandemic. I will definitely participate in the Electronics Fairs in April and October in the future."Turkish buyer and Co-founder of Robotistan Elektronik Tic AS, Yusuf Gündogdu, visited electronicAsia with a purchasing budget of around U$100,000-200,000 for electronic products. He said: "The Electronics Fair is the best opportunity for me to interact face-to-face with exhibitors from around the world. I always find the best prices here. Meeting the founders of start-ups in the Startup Zone excites me. These companies are poised to become some of the best in the future and will drive market development through innovation, which I eagerly look forward to."The organisers held 78 events and forums during the exhibitions, inviting industry leaders to share unique insights and the latest industry information. These events included the Symposium on Innovation & Technology, Hong Kong Electronic Forum and Reliability Assurance for Electronic Systems Forum. Other on-site activities catered to start-ups, including investment matching, the Hong Kong Value Creation for Technology: Pitching Competition, Meet the Mentors sessions and Start-up Smart Launch.Under the EXHIBITION+ hybrid model, exhibitors and buyers can use the Click2Match smart business matching platform to conduct online meetings, in addition to attending the physical fair. Exhibitors and buyers can still explore business opportunities and conduct online negotiations through Click2Match until 23 October.Photo Download:https://bit.ly/3BVmX2RHong Kong Electronics Fair (Autumn Edition) and electronicAsia successfully concluded. The four-day events attracted over 60,000 buyers from 136 countries and regionsThis year's Symposium on Innovation & Technology, themed 'When Two Worlds Collide: The Confluence of Digital Twins & Real-Life Applications', featured heavyweight guests and attracted numerous industry professionalsThe Hall of Fame gathered consumer electronic products from renowned brands worldwide. Among them, Asia Kingston (HK) Limited, specialising in brand licensing, presented a gaming chair featuring the NASA logoLocal brands, including well-known electronic brand Momax, promoted their products to global buyersThe Tech Hall showcased products using a variety of cutting-edge technologies, including 3D printing, Internet of Things, robotics, AR and XRThis year's Electronics Fair introduced a Digital Entertainment Experience Zone, where buyers could try and explore products on-siteThe concurrent electronicAsia featured multiple zones, exhibiting products, such as electronic components and parts, keyboards and switches, power supply equipment and moreThe Hong Kong Electronic Forum, co-organised by the HKTDC, MMI Asia Pte Ltd and the Hong Kong Electronic Industries Association, was themed “Innovation Unleashed: The Intersection of Microelectronics, AI, and Open-Source Ecosystems”WebsitesHong Kong Electronics Fair (Autumn Edition):  hkelectronicsfairae/enelectronicAsia: electronicasia/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Katy WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgSnowy ChanTel: (852) 2584 4525Email: snowy.sn.chan@hktdc.orgHKTDC Media Room: https://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong ’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly SMEs, in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - Guotai Junan International Holdings Limited (“Guotai Junan International”, “GTJAI”, the “Company” or the “Group”, stock code: 1788.HK) is pleased to announce that the Company has participated in the Good Employer Charter Scheme launched by the Hong Kong Labour Department for the sixth consecutive year, committed to adopting good personnel management practices and creating a family-friendly working environment for employees.The Good Employer Charter 2024 features the theme of “Supportive Family-friendly Good Employer”. Employers of different industries and scales are encouraged to adopt and enhance employee-oriented family-friendly employment practices, putting themselves in the employees’ shoes in discharging both work and family obligations, so as to create a family-friendly working environment. This signing of the Good Employer Charter demonstrates the Company’s efforts in employee care and creating a harmonious and inclusive working environment.GTJAI has always cared for its employees. Adhering to the business philosophy of “Talent as the First Resource” and pursuing the talent concept of “People-oriented, Collaborative Cooperation”, GTJAI considers employees as its core asset and has always been devoted to creating an inclusive and healthy working environment, and providing adequate resources to support employees’ growth and development. In the future, GTJAI will continue to strive to improve employee satisfaction, create a more friendly working environment, and contribute to building a harmonious and inclusive society. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年10月17日 - (亞太商訊 via SeaPRwire.com) - 國泰君安國際控股有限公司（「國泰君安國際」、「公司」或「集團」，股份代號：1788.HK）欣然宣佈，公司連續第六年參與由香港勞工處推出的《好僱主約章》計劃，致力於採取良好的人事管理措施，並為員工營造家庭友善的工作環境。《好僱主約章》2024以「為你『家』『友』好僱主」為主題，鼓勵各行業及不同規模的僱主推行及優化以僱員為本的家庭友善僱佣措施，將心比己體諒僱員兼顧工作及家庭的責任，締造家庭友善的工作環境。此次簽署《好僱主約章》，展現了公司在員工關懷及營造和諧共融工作環境方面所做出的努力。國泰君安國際一直關愛員工，秉承「人才是第一資源」的經營理念，奉行「以人為本，協同協作」的人才理念，視員工為企業的核心資產，打造包容、健康的工作環境，並提供充足的資源支持員工的成長與發展。未來，國泰君安國際將繼續致力於提升員工滿意度，營造一個更加友善和諧的工作環境，為締造和諧共融的社會貢獻力量。 Copyright 2024 亞太商訊 via SeaPRwire.com.

- Eco Expo Asia is expected to attract over 300 exhibitors from 11 countries and regions with new exhibitor groups from Anhui Province and Norway- The Expo will feature three focal points: New Energy, Waste Management and Circular Economy, and ESG-related Services, in pursuit of achieving the dual carbon goals- Government officials, industry experts and business leaders from various countries and regions, including Belt and Road countries will attend the Eco Asia Conference- Talks and workshops on the last day of the Expo (2 November) will be open to the public for freeHONG KONG, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - Eco Expo Asia 2024, jointly organised by the Hong Kong Trade Development Council (HKTDC) and Messe Frankfurt (HK) Ltd and co-organised by the Environment and Ecology Bureau of the Government of the Hong Kong Special Administrative Region (HKSAR), will be held at AsiaWorld-Expo from 30 October to 2 November. The last day of the event will be open to the public for free.To extend the sourcing journey, exhibitors and buyers worldwide can connect via the Click2Match virtual business matching platform from 23 October to 9 November.HKTDC Assistant Executive Director Jenny Koo said: "In the face of climate change, countries and regions have been actively propelling carbon reduction policies and sustainable development. China, for instance, set carbon reduction and neutrality goals in 2020 and has been advocating the development of new quality productive forces. The Hong Kong SAR Government is also committed to achieving carbon neutrality before 2050, and the development of related industries has become increasingly diversified, laying a strong foundation for Hong Kong’s sustainable development. Themed Fostering Green Innovations for Carbon Neutrality, the 19th edition of Eco Expo Asia will bring together international exhibitors and industry professionals to showcase cutting-edge innovations and technologies that aim to achieve dual carbon goals.”Speaking at the press conference, the Deputy Director of the Environmental Protection Department of the HKSAR Government, Fong Kin-wa, expressed: "We hope the Eco Expo Asia could share with visitors and exhibitors from around the world, including Belt and Road countries and ASEAN countries, the latest green innovation for achieving carbon neutrality, with a view to promoting exchange and cooperation between governments and trade sectors on boosting green & low-carbon transformation, achieving sustainable development, and leading Hong Kong towards carbon neutrality.”Converging international exhibitors and government officials at Eco Expo AsiaThis year’s Expo is expected to attract over 300 exhibitors from 11 countries and regions including Mainland China, Hong Kong, Macao, Taiwan, Singapore, Germany, Finland, Norway, the Netherlands, the United States and Canada. Several provinces and cities from Mainland China will form pavilions, including the return of Guangzhou and Shenzhen. The Anhui Pavilion will debut with technologies focused on air quality, water treatment and quality management as well as new energy materials and equipment. Supported by Innovation Norway, the debut group participation from Norway will showcase technologies for water quality management and waste treatment.The Eco Asia Conference, held during the first three days of the exhibition, will provide a platform for government officials, industry experts and business leaders from various countries and regions to discuss key trends, including energy projections, green building technologies and the circular economy. The conference is supported by the Ministry of Ecology and Environment, National Development and Reform Commission, and Ministry of Industry and Information Technology of the People’s Republic of China. Officials from Belt and Road countries, including Malaysia, Laos, Saudi Arabia, Myanmar, Brunei and Vietnam will also attend the conference.Three focal points in pursuit of dual carbon goalsTo achieve dual carbon goals, the development of green energy and green transportation has become a global trend. New energy is a focus of this year’s exhibition and many innovative new energy-related products and technologies will be featured. For example, Hong Kong’s first hydrogen fuel cell street-cleaning vehicle will be showcased at the booth hosted by the Environment and Ecology Bureau in conjunction with other HKSAR government units.The Inner Mongolia Pavilion will showcase cutting-edge solutions in environmental protection, ecological restoration and new energy. Innovative technical solutions, such as hydrogen purification systems and carbon capture and storage equipment, will be highlighted at the Canada Pavilion. In the Green Transportation zone, GMI Motors Ltd and first-time exhibitor Xiamen Golden Dragon Bus Co. Ltd will present a variety of electric vehicles. Chun Yang International (HK) Company Ltd will demonstrate fast charging and mini wall-mounted EV chargers catering to different needs.Waste Management and Circular Economy is a second focal point of the Expo, with exhibitor Smart Farming HK Ltd showcasing fish feed made from food waste and a sustainable fish farming concept. First-time exhibitor Nanda (Hong Kong) Technology Corporation Ltd will feature a food waste biodegradation machine that can process up to 36,000 kg of food waste per day.The Sustainable Restaurant Awards 2024, the first of its kind in Hong Kong's F&B industry to recognise restaurants based on their carbon footprint, will be presented on the third day of the Expo.The third focal point of the Expo is ESG-related services which is experiencing strong demand.  Several world-leading certification and consultancy companies will exhibit for the first time, including SGS Hong Kong Ltd, Intertek Testing Services Hong Kong Ltd, TUV Rheinland Hong Kong Ltd and BSI Pacific Ltd to present their testing and certification services as well as ESG consulting and training programmes. ESG AI, an innovative tool launched by China Energy Conservation & Environmental Protection (Hong Kong) Investment Co. Ltd, makes use of big data analysis and other technologies to generate regulatory-compliant ESG reports in one click.Nurturing talent to inject fresh energyEco Expo Asia has long been a platform for start-ups to showcase their latest innovations. Hong Kong Science and Technology Parks Corporation will showcase products and technologies from 10 start-ups related to green transport, circular economy and energy efficiency.In the popular Start-up Zone, exhibitor Ezygreenpak Ltd will demonstrate its patented water-soluble non-woven packaging material that can be completely dissolved in 90°C hot water without leaving any harmful residue. BSF Innovation Ltd's organic green building powder, consisting of fibre and calcium extracted from insect shells and food waste, can be blended with traditional building materials to make eco-bricks, reducing the manufacturing process carbon emissions by around 40%.A series of seminars and workshops on Public DayTo encourage residents to adopt green living practices, talks and workshops will be held on the last day of the Expo (2 November), which are free and open to the public. A highlight will be the Dialogue with the Secretary for Environment and Ecology for school students. Experts will share their strategies and experience in tackling extreme weather. The public can also participate in a variety of green workshops and shop for green products at Green Mart.Photo download: https://bit.ly/3BWSrpjJenny Koo, Assistant Executive Director of the HKTDC, introduced Eco Expo Asia highlights at the press conference. She said Hong Kong’s environmental-related industries were expanding in diversity, establishing the groundwork for the city’s sustainable development.The Chief Executive’s 2024 Policy Address released yesterday emphasises the need to promote the development of new energy and expand the electric vehicle charging network. Ms Koo stated that the HKTDC has been committed to promoting sustainable development in the business sector. In October, the HKTDC will work closely with the Environmental and Ecology Bureau to hold Eco Expo Asia, and provide support services and sourcing platforms to assist industry players in promoting and sourcing green products and solutions. In addition to Eco Expo Asia, the HKTDC aims to facilitate international connections through large-scale flagship events, promoting Hong Kong's role as an international centre for green finance and green technologyJenny Koo, Assistant Executive Director, HKTDC (centre); Fong Kin-wa, Deputy Director of the Environmental Protection Department of the HKSAR Government (left), and Judy Cheung, Deputy General Manager, Messe Frankfurt (HK) Ltd (right), attended the press conferenceGMI Motors Ltd displayed a brand-new, 32-seater electric bus with a large capacity batteryStart-up Ezygreenpak Ltd demonstrated its innovative water-soluble non-woven packaging material that can completely dissolve in 90°C hot waterTen companies resident at Hong Kong Science and Technology Parks Corporation sites will take part in the exhibition. Growgreen Ltd and One Energy (HK) Ltd showcased products related to circular economy and green transportation at the press conferenceSmart Farming HK Ltd introduced food waste recycled feed and fish farming sustainabilityWebsiteEco Expo Asia: www.ecoexpoasia.comMedia enquiriesPlease contact the HKTDC’s Communications and Public Affairs Department:Stanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgClayton Lauw     Tel: (852) 2584 4472  Email: clayton.y.lauw@hktdc.orgThe HKTDC’s Media Room:  http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences, and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.Background information on Messe FrankfurtThe Messe Frankfurt Group is one of the world’s leading trade fair, congress and event organisers with their own exhibition grounds. With a workforce of some 2,160 people at its headquarters in Frankfurt am Main and in 28 subsidiaries, it organises events around the world. Group sales in financial year 2022 were around €454 million. We serve our customers’ business interests efficiently within the framework of our Fairs & Events, Locations and Services business fields. One of Messe Frankfurt’s key strengths is its powerful and closely knit global sales network, which covers around 180 countries in all regions of the world. Our comprehensive range of services – both onsite and online – ensures that customers worldwide enjoy consistently high quality and flexibility when planning, organising and running their events. We are using our digital expertise to develop new business models. The wide range of services includes renting exhibition grounds, trade fair construction and marketing, personnel and food services. Sustainability is a central pillar of our corporate strategy. Here, we strike a healthy balance between ecological and economic interests, social responsibility and diversity.For more information, please visit our website at: www.messefrankfurt.com/sustainability. With its headquarters in Frankfurt am Main, the company is owned by the City of Frankfurt (60 percent) and the State of Hesse (40 percent). For more information, please visit our website at: www.messefrankfurt.com Copyright 2024 ACN Newswire via SeaPRwire.com.

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - October 16, 2024) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to provide a business update on the commercialisation progress of THERMAL-XR® Powered by GMG Graphene.CUSTOMER ENGAGEMENT UPDATEGMG continues to carry out both Supply and Service Coating for various Air Conditioning Manufacturers, Distributors, Contractors and end equipment owners - including the large HVACR condensing units showing the black coating of THERMAL-XR on the condenser coils seen in Figure 1.Figure 1: GMG Team Members in front of large HVACR condensing units coated with THERMAL-XRTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/226793_4a202364a43cd862_001full.jpgAt an event on 4th October 2024 in Brisbane, Australia that included the broad participation of HVAC industry representatives, GMG successfully RE-launched THERMAL-XR® ENHANCE. The focus of the event was on Thermal-XR's unique heat transfer and corrosion protection capabilities. When first developed, the product was named THERMAL-XR® RESTORE because the Company believed its principal benefit was to restore the heat transfer capabilities of existing installed air conditioners. However, GMG has since proved with third party verification that the product can also enhance the heat transfer of new equipment; hence the re-branding to THERMAL-XR® ENHANCE.As a result, GMG now believes that THERMAL-XR® ENHANCE has exciting opportunities with HVAC Original Equipment Manufacturers ("OEMs") in addition to its potential in the HVAC aftermarket. Over the past several months, GMG has completed on-site testing of THERMAL-XR® with global Air Conditioning Manufacturers in China and the USA for potential introduction into their factories. While further customer testing will be required, GMG believes early results are promising.Apart from applications in the HVAC industry, the unique heat transfer capabilities of THERMAL-XR® ENHANCE has also led to potential new applications in a wide range of industries where reducing heat is important. For example, customer managed Third Party Laboratory Testing with THERMAL-XR® is now being done with companies that operate LNG facilities; companies that manufacture electronic products; and companies that produce motors for the industrial and automotive markets. Further testing will be required to confirm the benefits of using THERMAL-XR® ENHANCE in such applications.Figure 2: RE-LAUNCH of THERMAL-XR® ENHANCETo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/226793_4a202364a43cd862_002full.jpgAs shown in Figure 2, THERMAL-XR® ENHANCE will now be available in 5 litre pails, instead of the original 10 litre containers. Customers have expressed their preference for lighter weight pails because they believe they are easier to lift onto roof tops for spraying in-situ air conditioners. Generally, 5 Litres of THERMAL-XR can be used to spray up to 5 small to medium size air conditioners, covering approximately 50 square metres of solid plate.As previously announced, GMG and Nu Calgon have signed an agreement and are working with a consultant to prepare and submit a Pre-Manufacture Notice ("PMN") in conjunction with its USA Environmental Protection Agency's ("EPA") application to import and sell in the USA. The PMN application is expected to be submitted before the end of October, and the approval is expected to take less than 12 months. The PMN will be substantially different from the Low Volume Exemption ("LVE") PMN that was previously submitted by GMG. Unlike the LVE PMN application that was limited to 10 tons per annum and one application technique in the HVAC sector, the PMN EPA approval that GMG is now seeking will not be limited by volume, application and any one particular sector.INDUSTRY RECOGNITIONTHERMAL-XR® is a finalist in the AIRAH Product of the Year - to be announced on 21st November 2024. AIRAH, the Australian Institute of Refrigeration, Air Conditioning and Heating, is the peak body representing the HVAC&R industry in Australia. Officially incorporated by guarantee on March 29, 1920, AIRAH celebrated its Centenary anniversary in 2020.The AIRAH Awards provide our industry with the opportunity to reflect, applaud, and raise a toast to our peers and their achievements - from promising future leaders to established sector veterans; from the finest new projects to the best retrofits; as well as the greatest in refrigeration, renewable energy, and research. Independent industry specialists determine a shortlist of finalists, from which a winner is selected by an expert judging panel. This rigorous and impartial process makes the AIRAH Awards the most highly prized accolades in Australia's HVAC&R building services industry.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/226793_4a202364a43cd862_003full.jpgGMG's Managing Director and CEO, Craig Nicol, commented: "We believe GMG continues to make good progress in testing its products in large global OEM's for various types of products in various applications whilst our technical understanding of the coating improves - creating an exciting cycle of innovation and learning with our customers and how we make the graphene and coating, how it is applied and also how it is marketed and sold."GMG's Chairman and Director, Jack Perkowski, commented: "THERMAL-XR® testing in so many of these applications is very exciting to see and I am encouraged by its potential for progress in these markets."TEAM UPDATEGMG would like to thank Bobby Bran, Chief Projects Officer ("CPO"), for his near 6-year service at the Company. In the Company's continued efforts to transform into a commercial operation, the Company has decided to outsource major project activity going forward and as such will no longer need a CPO.On behalf of GMG and its Board of Directors, Craig Nicol and Jack Perkowski would like to thank Bobby for his dedication and service during his near 6-year tenure at the Company.About THERMAL-XR® powered by GMG Graphene:THERMAL-XR® COATING SYSTEM is a unique method of improving the conductivity of corroded heat exchange surfaces and improving and maintaining the performance of new units at peak levels. The process coats and protects heat exchange surfaces while improving and rebuilding the lost corroded thermal conductivity and increasing the heat transfer rate by leveraging the physics of GMG Graphene, resulting in an efficiency improvement and a potential power reduction.THERMAL-XR RESTORE® is powered by GMG Graphene. PATENT PENDINGAbout GMG www.graphenemg.comGMG is a clean-technology company which seeks to offer energy saving and energy storage solutions, enabled by graphene, including that manufactured in-house via a proprietary production process. GMG has developed a proprietary production process to decompose natural gas (i.e. methane) into its elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating), lubricants and fluids.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries").GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking Statements This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the potential for THERMAL-XR® to enable energy producers to produce additional energy more efficiently, the potential for THERMAL-XR® ENHANCE to enhance the heat transfer of new equipment and its opportunities with HVAC industry and other industries where reducing heat is important, the timing of submission of the Company's PMN application, the receipt, timing and nature of approval by the EPA of the PMN application, the Company's goal of achieving optimal production line performance for THERMAL-XR® and the entering of full production. Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions regarding the development of extensions and enhancements to the THERMAL-XR® portfolio into a wider range of applications, that energy producers will be able to derive the expected benefits from the Company's products, that the Company's PMN application will be submitted on the timetable anticipated, that the EPA will approve the PMN application and on the timing anticipated, that the content of the EPA's approval will be as anticipated, and that the Company will be able to achieve optimal production line performance for THERMAL-XR® and enter full production. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that there will be no developments of extensions or enhancements to the THERMAL-XR® portfolio into a wider range of applications, that energy producers will not derive the expected benefits from the Company's products, that the Company's PMN application will not be submitted on the timetable anticipated or at all, that the EPA will not approve the PMN application on the timing anticipated or at all, that the content of the EPA's approval will not be as anticipated, that the Company will be unable to achieve optimal production line performance for THERMAL-XR® or enter full production, risks relating to the extent and duration of the conflict in Eastern Europe and its impact on global markets, the volatility of global capital markets, political instability, the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel, unexpected development and production challenges, unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226793 Copyright 2024 ACN Newswire via SeaPRwire.com.

- Eng Kong is the first depot in Singapore to trial and customised this technology, after several locations such as Korea's HMM PSA New-port Terminal in Busan who has also adopted similar technology.- The Singapore version is environmentally friendly as it will address carbon emissions, carbon footprint and reduce air pollution due to paperless processing.- Significant productivity, safety and manpower advantages with process times halved. Drivers can remain in their vehicles while streamlining the depot administration process.- Eng Kong plans to expand the system to its other Singapore depots by 1Q2025, potentially boosting efficiency and boosting throughput.SINGAPORE, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - EKH Pte Ltd. (“Eng Kong” or the “Company”, and together with its subsidiaries, the “Group”), one of Asia-Pacific’s largest shipping container depot operators, has installed and customised Singapore’s first automated container seal dispenser systems to fit their depot’s Container Management Systems (CMS) systems.The Group intends to expand the system to its other three Singapore depots by 1Q2025 and eventually its mega depot 3Q2026. Eng Kong’s mega depot, spanning 80,000 square metres, will be Singapore’s largest depot. The system will have significant productivity, safety and manpower advantages compared to traditional methods.Container seals are required to prevent theft and unauthorized access to the container contents. Previously, the seal collection process was highly manual, administrative and time-consuming, taking an average of 30 minutes before drivers could obtain seals.Eng Kong's wholly owned subsidiary, Eng Kong Container Agencies Pte Ltd, has installed and customised Singapore’s first fully automated seal dispenser system which has helped cut collection time by half. The system is fully localized for Eng Kong’s depots, ensuring seamless integration with their current logistics infrastructure.Drivers now follow a seamless and safer flow, and no longer need to disembark their vehicles - much like a drive through. Upon entering the depot, time-consuming procedures are now eased up with the use Automated Gate Registration, Acceptance and Payment Functions with the use of Depot Appointment Information and Licensed Plate Recognition (LTR) Licensed Plate Recognition (LPR) technology and a cashless payment system. The driver then collects and quality-checks the container and seals at the automated seal dispenser.Labour shortage pressures could be further eased through automation, drivers will be able to transport more containers, and administrative staff could be trained for more strategic positions.In Singapore, a total of 39.01 million TEUs were processed in 2023(1). At Eng Kong’s domestic depots, the introduction of automated seal dispensers is expected to significantly boost efficiency. As each minute saved per container adds up significantly, it has been estimated that this new initiative can save up to an estimated 50,000 of man-hours per annum for the entire process from the time the driver arrives, processing, mounting the containers and collecting the seal from the dispenser machine near the entrance. These time savings will enable for reskilling the staff to other job opportunities, enhancing workforce capabilities and booth the driver(s) earning, while increase efficiency.Additionally, Singapore’s handling capacity is expected to double once the PSA Tuas Port is completed in 2040(2). Traffic congestion around busy depots will be eased and safety for drivers improved as they no longer alight their vehicles. Labour shortage pressures could be further eased through automation, drivers will be able to transport more containers, and administrative staff could be trained for more strategic positions.Paul Ng, Co-Chairman of Eng Kong said, “As one of Singapore’s largest depot operators, we are committed to improving operational efficiency, reducing manual labour dependency and improving the safety of our depots. As Singapore’s depots transition to Tuas, which is set to be the world’s largest automated port, investing in automated solutions will allow Eng Kong to remain at the forefront of this digital transformation. The world is watching Singapore and depot operators have a role to play in embracing technology and integrating advanced solutions, driving progress across the industry.”(1) S’pore port handled record 39.01 million shipping containers in 2023, Straits Times, 13 Jan 2024(2) World’s largest automated terminal: PSA Tuas Port pioneering automation transformation with event-driven architecture, Seatrade Maritime News, 14 Feb 2024About Eng KongFounded in 1975, Eng Kong is an integrated logistics operator and a key provider of container related services to global firms operating in the Asia-Pacific region. In 1986, Eng Kong broadened its business portfolio to become regional player. Eng Kong operates 20 fully integrated container depots spanning across Singapore, China, Malaysia, Hong Kong, Thailand, and Vietnam, totalling 705,100 sq. meters.Eng Kong provides comprehensive depot related services such as storage and handling, repair and maintenance, and new build container inspection and survey. Transportation. Over the years, we have established a sound reputation for reliable, cost-efficient service.For more information, please visit https://www.engkong.com.                            Issued for and on behalf of EKH Pte. Ltd.By Financial PRFor more information, please contact:Kamal SAMUEL / LEE Ke Wei E-mail: kamal@financialpr.com.sg / kewei@financialpr.com.sgTel: +64 6438 2990 Copyright 2024 ACN Newswire via SeaPRwire.com.

東京, 2024年10月17日 - (亞太商訊 via SeaPRwire.com) - 田中貴金屬集團核心企業——以產業用貴金屬展開事業的田中貴金屬工業株式會社（總公司：東京都中央區，執行總裁：田中 浩一朗）宣布成功開發出應用於半導體封裝的後段中，進行最終測試的探針用鈀（Pd）合金材料「TK-SK」。本產品將於2024年10月24日至25日，在福岡縣舉辦的「SWTest Asia 2024」上進行展覽板展示，並預計於年底前開始提供樣品。田中貴金屬工業製造並提供各種貴金屬探針用材料，將其運用在半導體前段製程和後段製程中實施檢測的設備。本次將要宣布的「TK-SK」，作為探針用的鈀合金材料，具備最大硬度640HV，因此主要設定其用途為測試插座，應用於後製程中通電試驗的最終測試。近年來，雖然高硬度探針的需求不斷增加，但硬度越高，材料的加工就會愈加困難，像是進行切削加工時會發生破損這類的課題，且目前在市場上流通的鈀合金類材料的硬度，最大只到560HV左右。此次，田中貴金屬工業利用獨特的加工技術，已成功將本產品的硬度開發到640HV。針對本產品，本公司目標於2028年前達到既有產品出貨量的1.5倍。對於測試插座，用來當作探針的是彈簧針（POGO PIN）型的探針。進行檢測時，由於探針的尖端（Plunger）與基板接觸時會產生摩擦，就會因磨損而變形。此外，銲錫材料可能會附著在Plunger上，需要刮掉銲錫材料進行清潔，此時Plunger也會因磨損而變形。檢測設備的探針會因檢測過程導致變形，而需要定期維護，但透過使用高硬度的探針，可以降低減輕半導體檢查設備中的探針因磨損造成的變形，可期貢獻於檢測設備的長壽命化與低成本化。今後，半導體市場預計仍將不斷擴大，田中貴金屬工業的目標即是為其發展做出貢獻。「TK-SK」產品性質參考值參展展示會詳情展示會名稱：SWTest Asia 2024展覽期間：2024年10月24日10:00～15:30、10月25日10:00～16:00會場：福岡海鷹希爾頓飯店（福岡縣福岡市）官方網站：https://www.swtestasia.org/參展公司：田中貴金屬工業株式會社攤位編號：210展覽板展示內容：探針用鈀合材料「TK-SK（線）、TK-FS（線、板）」、探針用銅銀合金材料「TK-101（板）」、探針卡用貴金屬電鍍液關於田中貴金屬集團田中貴金屬集團自1885年（明治18年）創業以來，營業範圍向來以貴金屬為中心，並以此展開廣泛 活動。在日本國內，以最高水準的貴金屬交易量為傲的田中貴金屬集團，長年以來除了進行產業用貴 金屬產品的製造和販售外，也供應貴金屬製作珠寶飾品和投資型貴金屬商品。本集團以貴金屬專業團隊之姿，旗下的國內外各集團公司協調合作，使製造、販售與技術一體化，並供應相關產品與服務。2023 年度（2023年12月止）的合併營業額為6,111億日圓，擁有5,355名員工。產業事業全球網站https://tanaka-preciousmetals.com/tw/產品諮詢表田中貴金屬工業株式會社https://tanaka-preciousmetals.com/tw/inquiries-on-industrial-products/新聞媒體諮詢處田中控股株式會社https://tanaka-preciousmetals.com/tw/inquiries-for-media/新聞稿: https://www.acnnewswire.com/docs/files/20241017_CT.pdf  Copyright 2024 亞太商訊 via SeaPRwire.com.

ATH-063在所有劑量水平下顯著增加了循環調節性T細胞（Tregs）的數量，並在六個與誘導Treg抗炎活性相關的已知基因中表現出富集在任何劑量水平下，未觀察到嚴重不良反應或劑量限制性毒性，且ATH-063表現出良好的藥代動力學（PK）這些數據為Athos專有的AI2（用於自身免疫藥物開發的人工智慧）計算軟體平台生成的ATH-063提供了臨床驗證洛杉磯, 2024年10月17日 - (亞太商訊 via SeaPRwire.com) - Athos Therapeutics, Inc.（“Athos”），一家處於臨床階段的生物技術公司，致力於為免疫介導疾病患者開發精準的小分子療法，今天宣布了公司I期臨床試驗的頂線結果。該試驗涉及ATH-063，這是一種正在開發中的口服小分子G9A抑制劑，也是公司為治療炎症性腸病（IBD）開發的主要資產。該臨床試驗是一項在健康志願者中進行的隨機、雙盲、安慰劑對照研究，旨在評估其安全性和藥代動力學（PK），並提供藥效動力學（PD）數據，以確認ATH-063的擬議作用機制。試驗採用了順序的單劑量遞增（SAD，n=32）和多劑量遞增（MAD，n=32）組，並設有一個單獨的食物效應（FE，n=12）組。ATH-063以四種劑量（25、75、150和250毫克）口服給藥。藥效動力學（PD）數據表明，ATH-063對調節性T細胞（Tregs）的選擇性擴增和激活與Athos AI2平台的預測一致：與安慰劑組相比，所有ATH-063劑量水平下的血液調節性T細胞（Tregs）數量均顯著增加（p<0.001），並顯示出ATH-063血液濃度與Tregs數量之間的相關性。ATH-063血液濃度與多個調節性T細胞（Tregs）活性關鍵生物標誌物的增加呈正相關，其中與FOXP3的相關性較強（p=0.003）。誘導的調節性T細胞（Tregs）在六個與Treg抗炎活性相關的已知基因中表現出富集。STAT5A，這一與誘導調節性T細胞（Tregs）相關的關鍵信號分子，在所有隊列和劑量中均被激活（p=0.0003）。藥效動力學（PD）數據表明與炎症性腸病（IBD）疾病活動性關鍵生物標誌物的相關性，支持進一步開發ATH-063作為IBD的治療藥物ATH-063血液濃度與OSM的減少呈相關性（p=0.012），OSM是與TNFA耐藥相關的一個已知生物標誌物ATH-063血液濃度與鈣衛蛋白單體的減少呈相關性，鈣衛蛋白是炎症性腸病（IBD）的一個已知生物標誌物ATH-063在所有劑量組中均具有良好的耐受性：在任何劑量水平下，未觀察到嚴重不良反應或劑量限制性毒性。 強勁的藥代動力學（PK）結果和劑量成比例的血液水平增加：ATH-063在整個研究過程中顯示出良好的藥代動力學結果，血液中ATH-063濃度隨劑量成比例增加。“我們的ATH-063首次人體臨床試驗結果超出了我們的高度預期，”Athos創始人、總裁兼首席執行官Dimitrios Iliopoulos博士（PhD，MBA）表示。“我們利用Athos AI2藥物開發平台，識別了一個之前未被發現的全新治療靶點，創造了ATH-063，並在臨床前預測了該化合物的擬定作用機制。我們很高興這些I期結果為Athos AI2計算引擎所做的預測提供了臨床驗證，”Iliopoulos博士補充道。“我們的I期數據表明，ATH-063每日口服給藥具有良好的耐受性，並表現出調節性T細胞（Tregs）的擴增，”Athos創始人兼首席醫學官Allan Pantuck博士（MD，MS，FACS）評論道。“我們很高興進入下一階段的臨床開發，針對中度至重度活動性潰瘍性結腸炎患者。ATH-063項目從最初的靶點識別到完成I期臨床試驗的快速進展，得益於我們利用人工智慧進行藥物開發的創新方法。”關於ATH-063ATH-063是一種新型的、正在研究中的、由人工智慧生成的口服小分子G9A抑制劑，正在開發用於治療炎症性腸病（IBD）和其他自身免疫性疾病。G9A是一個基因網絡的核心節點，該基因網絡通過Athos的AI2平台整合Athos IBD生物庫的多組學和縱向臨床數據被識別出來。ATH-063旨在通過擴增和激活調節性T細胞，直接靶向人類CD4 T細胞和胃腸道上皮細胞中的G9A酶活性，既抑制促炎反應，又通過調節緊密連接蛋白誘導直接的粘膜癒合。關於Athos Therapeutics Athos Therapeutics是一家處於臨床階段的生物技術公司，致力於開發可能成為首創的療法，從而顯著改善自身免疫性疾病和慢性炎症性疾病患者的生活。Athos的藥物開發平台始於從全球頂級醫院系統獲取的超過25,000個高質量患者樣本。Athos的AI2平台通過整合多組學和縱向臨床數據集來識別新的藥物靶點，並將其與小分子計算化學平台相匹配。AI2平台包括Athos的數據湖、已建立的獨特組學工作流程以及整合的深度機器學習引擎。公司的主要藥物化合物是ATH-063，一種用於治療炎症性腸病的口服小分子G9A抑制劑。此外，Athos還在開發一系列針對各種自身免疫性疾病的小分子療法。 關於Athos Therapeutics的更多資訊，請訪問 https://athostx.com/ 聯繫方式：Athos Therapeutics, Inc.Keith Hoffman, PhD, Chief Business Officerkhoffman@athostx.com 資料來源：Athos Therapeutics， Inc. Copyright 2024 亞太商訊 via SeaPRwire.com.

香港, 2024年10月16日 - (亞太商訊 via SeaPRwire.com) - 香港董事學會就2024年10月16日發表之《施政報告》作出回應。行政長官李家超先生今日發表任内第三份施政報告，篇幅頗長，主要在於深化推進既有長遠發展策略及相關措施。然而，長遠發展收效需時。故此，施政報告有不少短中期措施扶穩經濟。中長期發展本港長遠發展，重中之重，是努力發展成爲國際創新科技中心，以新質生產力體現高質量經濟發展。其中，政府將制訂新型工業中長期發展方案，推動成立新型工業發展聯盟，促進「政、產、學、研、投」緊密合作，完善新型工業發展策略和體制。另方面，施政報告提到，政府將擴大研究配對資助，加大創科產業投資，成立100億元「創科產業引導基金」，優化「創科創投基金」，推出「創科加速器先導計劃」，應有助創科及新型工業發展。短中期措施行政長官已經向中央提出，優化内地居民來港旅游簽注的請求，包括恢復「一簽多行」個人游簽注及增加「一周一行」個人游簽注試點城市，爭取更多入境旅客。行政長官也提到，將放寬簽證門檻，吸引更多東盟地區旅客來港。越多高端旅客願意來港，不論是商務差旅抑或消閑游玩，都是好事。高端旅客最重體驗。若論高端旅客，中東地區應會是一大來源。他們在港是否容易獲得符合清真教義及禮拜需要的設施配套，好可能直接影響他們對香港的印象，是否值得再來或推薦更多人來。行政長官提到，發展盛事旅游經濟，既要重質亦要重量。事實上， 「盛事」標簽不能用的太濫，但旅客來港參加真正盛事之時，有其它不同類型的大小活動順道參加，可以吸引旅客多留一兩天。施政報告推出一系列措施支援中小企，包括再推「還息不還本」融資擔保安排，及向「BUD專項基金」注資10億元等。行政長官又提到，金管局正積極考慮就銀行資本要求提供彈性，促進銀行為中小企提供融資。我們相信，相關措施，可以幫助中小企應對經濟轉型的融資需要。行政長官又提到，推動數字經濟與實體經濟融合發展，例如加速發展數字貿易。擴大「數碼轉型先導計劃」的涵蓋範圍，應該會幫助更多中小企實現數字轉型。政府又將成立「促進銀髮經濟工作組」，由政務司副司長任組長，循消費、產業、生產力等五方面推出措施，開拓新的產品和服務滿足長者需要，並創造商機。至於「釋放銀色生產動力」的想法，我們贊同。我們認爲，本港人口老化問題越見嚴重，有長者需要合適政策措施得以照顧安老。但應對老齡化的總體政策應以幫助更多長者打破銀色天花板為目標，給予年紀漸大但仍有心有力的長者空間和機會充實暮年生活，做他們想做想幹的事，不因年齡成爲障礙。施政報告有若干措施，鞏固國際金融中心地位，例如便利市民跨境金融安排、建立國際黃金交易市場、提升綠色金融生態系統、建立大宗商品交易生態圈等。優化證券市場的措施，包括優化上市審批流程，爭取更多企業來港上市。我們認爲，除了内地企業，若能吸引更多支持共建一帶一路的國家地區的企業來港上市，會是好事。下調烈酒稅須顧及公共健康行政長官宣佈，局部下調烈酒稅，進口價200元以上從價稅率減至10%，估計有8成多烈酒的稅率不受影響。學會並不同意全面減免烈酒稅，但可以同意，今次減稅方案或對高價烈酒提供比較公平的競爭環境。有政界人士或以此認爲方案聰明，是耶非耶，仍是見仁見智。高價烈酒與低價烈酒，同樣有害健康。日前有議員認爲，為高價酒提供稅惠，可以鼓勵店商引入好酒，可以教育市民分辨好酒云云。按此説法，開放足球以外更多運動球類博彩也不會鼓勵賭博，反而會教育市民什麽是好球。但我們留意到，政府需要不時播放公共宣傳廣告，勸諭市民不要沉迷賭博，並提供戒賭輔導相關信息。我們期望政府當局預留資源，提前制訂措施，應對減烈酒稅後可能多了人會喝酒、喝多了酒而產生的公共健康負面影響。取締劣質劏房醖釀多時，行政長官今日宣佈，將推出住宅樓宇分間單位出租制度，銳意取締劣質劏房，而合符最低規格的將成爲被認證、受規管的「簡樸房」。我們期待政府公佈更多細節，而各界也肯定會仔細斟酌最低規格的標準和定義。劏房的存在，絕不是香港的光榮。改革體育總會管治施政報告同持提出研究設立體育爭議解決制度，學會表示支持，學會也樂意配合政府推動體育發展。其中，香港董事學會一直以來都為體育總會及界別内其它機構提供培訓及特定的管治諮詢服務，于未來也會繼續協助為體育總會及相關機構落實新制訂的《機構管治守則》，完善管治水平。經濟發展去改善民生行政長官于今日下午的記者會，開宗明義，說出要以經濟發展去改善民生。學會一直認爲，經濟持續增長是尋找資源以解決房屋、貧窮、老年社會和環境等民生問題的最可倚仗的夥伴。行政長官上任以來推行不少政策措施解決積纍已久的經濟、民生問題，我們表示欣賞。然而，實際效果需要時間才能驗證，期間更需財政、人力等資源配合。我們期望經濟能儘快回復動力，給下一個財政預算案更多資源彈性，更好更快落實行政長官的施政方向。香港董事學會（簡稱"HKIoD"，又以下簡稱「學會」）香港董事學會為香港代表董事共同努力的首要組織，其宗旨是促進企業永續發展職能，為所有公司、其擁有者、持份者、人類以至地球創造持久價值；為達成使命，學會致力於企業管治（「企業管治」又稱「公司治理」）及董事專業行為上的倡導及釐定相關標準。學會於1997年由創會主席鄭慕智博士帶領下創始，多年來非常榮幸獲得香港特別行政區行政長官擔任學會贊助人。學會會員來自不同行業及公司類別，並包括執行董事、非執行董事、獨立非執行董事。學會以多元文化及國際視野進行會務，舉辦活動包括董事培訓課程、研討會與論壇、董事立場喉舌、指引設定、公眾教育、董事嘉獎系列、上市公司管治水平釐定等。作為「董事學會環球網絡」（Global Network of Director Institutes 簡稱"GNDI")的成員組織，學會投入全球性聯手推動優秀企業管治及董事專業行為。學會亦獲委派代辦「氣候管治行動」(Climate Governance Initiative)之香港分部，該行動是與「世界經濟論壇」（World Economic Forum）合作的環球網絡，積極促進董事們處理氣候變化帶來的風險與機遇。詳情請瀏覽：http://www.hkiod.com | http://www.gndi.org | https://climate-governance.org/新聞垂詢:香港董事學會王俊泳2889 1414/wing.wong@hkiod.com Copyright 2024 亞太商訊 via SeaPRwire.com.

HONG KONG, Oct 16, 2024 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (HKTDC) welcomes the 2024 Policy Address, delivered today by the Hong Kong Special Administrative Region’s (HKSAR) Chief Executive John Lee.The Policy Address presents a comprehensive set of measures, ranging from the economy and trade and people’s livelihood to high-calibre talent attraction and youth development. Leveraging Hong Kong’s one country, two systems advantages, the policies will fuel the city’s continued economic growth.Dr Peter K N Lam, Chairman of the HKTDC, said: “The Policy Address highlights the Hong Kong SAR Government’s efforts in seeking innovation and change, while striving for excellence. It addresses a wide range of areas covering economic growth, trade and investment, SME support, culture and creative as well as construction and planning. Riding on Hong Kong’s eight centre advantages, the Policy Address promotes new quality productive forces and high-quality economic development.”The annual address announced various measures to reinforce the city’s status as an international financial, shipping and trading centre. Dr Lam believed the move echoes the 20th Central Committee’s Third Plenary Session’s Resolution to develop Hong Kong into a supply chain service centre: “The HKTDC will continue to proactively promote Hong Kong’s eight centre advantages and enhance the development of high value-added supply chain services. We will step up cooperation with InvestHK to set up a mechanism and enhance the interface for attracting mainland enterprises to establish their international or regional headquarters in Hong Kong and provide one-stop diversified professional advisory services to help them go global via the Hong Kong platform.”He added that the HKTDC will strengthen advisory services of its Transformation Sandbox (T-box) programme to cover a wider range of areas and support Hong Kong enterprises as well as mainland companies in Hong Kong in regard to business transformation, sustainable development and operational upgrade. Businesses are encouraged to leverage the HKTDC’s trade platforms and events to go global and explore international market opportunities, especially in the high-potential ASEAN region.Dr Lam welcomed the HKSAR Government’s SME support measures, including the relaunch of the Principal Moratorium scheme, a HK$1 billion injection into the BUD Fund and an additional HK$500 million provision for the Incentive Scheme for Recurrent Exhibitions 2.0. He believes the measures will foster SMEs’ sustainable development and reinforce Hong Kong’s role as a leading convention and exhibition hub.The Policy Address stated the Hong Kong Shopping Festival will be relaunched in the next two years to help SMEs tap into the mainland e-commerce sales market. Dr Lam said: “The inaugural Hong Kong Shopping Festival organised by the HKTDC in August this year received an enthusiastic response. Not only did it raise participants’ brand exposure, but also provided them with practical experience in e-commerce operations. We will build on this year’s success and host the second edition of the Festival next August, and in the ASEAN market in due course, to enable Hong Kong SMEs to explore market opportunities via e-commerce and social media platforms.”To help SMEs understand e-commerce marketing, the HKTDC will publish research reports and analyses on e-commerce ecosystems in different markets, such as ASEAN, to help businesses lay a solid foundation in e-commerce operations. Through its Digital Academy and Design Gallery’s (DG) cross-border e-commerce shops on Taobao and JD International, the HKTDC has been offering comprehensive support to Hong Kong SMEs to leverage diverse e-commerce and digital marketing channels to explore mainland opportunities. DG’s 70 physical sales network in the mainland serve as an ideal platform to promote Hong Kong brands in the region. As for the ASEAN market, the HKTDC’s DG Studio programme helps connect local businesses with ASEAN physical retailers and e-commerce platforms.In terms of strengthening SMEs’ brand development, the HKTDC will continue to organise some 40 international exhibitions and conferences in Hong Kong every year. We will also set up more Hong Kong Pavilions in mainland and overseas exhibitions and further enhance business matching, to support SMEs in developing their brand and tapping global opportunities.On promotion of Hong Kong's cultural and creative industries, as mentioned in the Policy Address, more Hong Kong, mainland and overseas cultural and creative products will be added to the Asia IP Exchange (AsiaIPEX), managed by the HKTDC, to facilitate cross-sector exchanges and cooperation and contribute to Hong Kong’s development into a regional IP trading centre. Currently, the platform displays more than 28,000 IP projects available for trading. The HKTDC will continue to promote cultural and creative products as well as IP transformation and trading on its platforms, such as the Business of IP Asia Forum, Hong Kong International Licensing Show and the Hong Kong International Film and TV Market.Dr Lam also welcomed measures addressing new quality productive forces, the Northern Metropolis, digital economy and silver economy, which will help Hong Kong businesses further explore opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area and Belt and Road countries and regions.Addressing the reduction of the liquor duty rate, Dr Lam believes that the move will strengthen related trade and further promote Hong Kong as a regional wine trading hub. He added that the 16th Hong Kong International Wine and Spirits Fair will be held from 7 to 9 November, which will showcase fine wines from around the world, including liquors and white wines in the mainland pavilions, whiskeys from Japan and Ireland and spirits from around the world. Fair seminars will highlight the prospects of Hong Kong’s spirits market, while Chinese liquor promotional events will help the industry seize new opportunities.In conclusion, Dr Lam said: "The HKTDC will continue to support and complement national development and the Hong Kong SAR Government's policies. We will work closely with the business community to leverage Hong Kong's advantages and promote sustainable economic growth."Media enquiriesPlease contact the HKTDC’s Communication & Public Affairs Department:Sam HoTel: (852) 2584 4589Email: sam.sy.ho@hktdc.orgTo view press releases in Chinese, please visit http://mediaroom.hktdc.com/tcAbout HKTDC The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2024 ACN Newswire via SeaPRwire.com.